NIKA · Nika Pharmaceuticals, Inc · Shareholders & Ownership
Substantial doubt about the company's ability to continue as a going concern.
“These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.”View the 10-Q filed Aug 10, 2026
Every disclosed holder of NIKA in one list: 13F institutions, Schedule 13D and 13G filers, insiders (Forms 3, 4 and 5) and registered funds, each from its own latest filing. Holders nest by CIK and SEC reporting links, never by name, and each is summed once.
Who Owns NIKA
| Holder group | Shares | % Out |
|---|---|---|
| Institutional (13F) | 0 | 0.00% |
| Insiders (Forms 3, 4, 5) | 455,589,500 | 43.32% |
| 13D/G-only blocks | 0 | 0.00% |
| Remaining | 596,099,724 | 56.68% |
| Registered funds (N-PORT, not summed) | 0 | 0.00% |
Shares outstanding: 1,051,689,224, the issuer's latest cover-page count restated onto today's split basis.
13D/G-only counts each filer's latest 13D or 13G that no 13F report of the listing contains, that names no 13F filer and that no counted insider files. Funds are never summed: their shares sit inside their advisers' 13F reports.
Holders of NIKA
| # | Holder | Shares | As of | Notes |
|---|---|---|---|---|
| 1 |
Savov Dimitar Slavchev
Insider
CIK 2019433 · Mar 18, 2025
Director, CEO, CFO, President, 10% Owner, issuer-wide
|
455,589,500 |
Shares are restated onto today's split basis. Change compares each row with the same holder's previous filing in the same source; a dash means there is none to compare. Nested 13D/G, insider and fund rows are not summed, since a 13F report already holds them.